Xoc Pharmaceuticals is a technology company.
Xoc Pharmaceuticals has raised $30.0M across 1 funding round.
Xoc Pharmaceuticals has raised $30.0M in total across 1 funding round.
Xoc Pharmaceuticals has raised $30.0M in total across 1 funding round.
Xoc Pharmaceuticals's investors include Qiming Venture Partners.
Xoc Pharmaceuticals is an early-stage biopharmaceutical company developing innovative oral therapeutics from the ground up, leveraging data on existing compounds to address unmet needs in central nervous system (CNS) disorders.[1][2] Its lead programs target migraine prevention with XC-101 and Parkinson’s disease maintenance with XC130-A10H, serving patients with these debilitating conditions by designing novel molecules with established pharmacological profiles for improved safety and efficacy.[1][4] Based in Los Gatos, California, the company emphasizes scalable production, regulatory compliance, and technological advancement, operating with around $6 million in funding and backed by investors like NEA.[1][2][3]
Xoc Pharmaceuticals emerged as a Bay Area-based biotech firm focused on CNS therapeutics, with initial programs launching around 2019, as indicated by clinical start dates for its pipeline assets on August 11 and October 8.[4] While specific founders are not detailed in available records, the company's proprietary design process repurposes insights from clinically validated compounds to create de novo products, marking a pivotal shift toward efficient drug development for migraine and Parkinson's.[1][4] Early traction includes NEA's portfolio inclusion and progression of XC-101 and XC130-A10H to pending phases, signaling investor confidence in its ground-up innovation approach.[1]
Xoc rides the wave of repurposing and de novo CNS drug design, capitalizing on AI-enabled pharmacology data to accelerate therapies amid rising demand for migraine (affecting 1B+ globally) and Parkinson's (10M+ cases) treatments.[1][4] Timing aligns with post-2020 biotech funding resurgence and regulatory pushes for efficient CNS pipelines, where traditional discovery fails 90%+ of candidates—Xoc's approach mitigates this by leveraging proven compound insights.[1] It contributes to the Bay Area's biopharma ecosystem by advancing oral alternatives to injectables, potentially influencing investor shifts toward data-driven, multi-target CNS innovation.
Xoc is poised to advance XC-101 and XC130-A10H into clinical readouts, with pending phases signaling near-term milestones amid CNS market growth projected at 8% CAGR through 2030. Trends like AI-drug design and oral CNS therapies will propel it, potentially expanding to adjacent indications if Phase 1/2 data validates its platform. As NEA-backed early-stagers scale, Xoc could evolve from niche innovator to broader CNS player, reshaping unmet needs with its repurposing edge—watch for trial initiations to confirm momentum.
Xoc Pharmaceuticals has raised $30.0M across 1 funding round. Most recently, it raised $30.0M Series A in February 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2018 | $30.0M Series A | Qiming Venture Partners |